no problem 22 ji

jado lucha killer ban hogya ohdo fir tu rajj kari pj tee :laugh: :laugh: :laugh: :laugh:

no pro broo anytime  :happy: :hug:

he my friend jatti

i understand 22 ji but oh ne kuch kita nhi c eda ban karta

hun a id ban kiti haa fir oh ne diffrent id ban ban ke ao gya fir kina var banned karo gye

lucha killer nu ma he la ke aya pata nhi kyu banda karta can u unbann

ohkk 22 ji but why ur fav number 15

Mumbai August 14:
            Sachin Tendulkar has welcomed Cricket Australia's move to split a one-day innings into two halves. He feels once the method is put into practice, the players will be able to figure out how good the new system is.
Also read: ‘Australia cricketers irked by new one-day format’ Speaking to reporters, the master batsman said, "I am glad it's being tried out in Australia. I feel once the players have tried out this format, they will be in a better position to judge if the format works or not."
Tendulkar was one of the first cricketers to suggest that one-dayers should be split into two innings in September 2009. The 37-year-old had said that the idea first struck him in 2002 when the final of the Champions Trophy between India and Sri Lanka could not be completed despite 110 overs of cricket being played over two days. "First, they played 50 overs and we played two overs before the rain interruption. The next day, Sri Lanka again played 50 overs and we played eight.
In the end we were declared joint winners. 110 overs and still no result! That is when I thought we should have 25 overs first for one side and then the other. And then once again 25 overs for one side and then the other," he had explained. Tendulkar feels that the new formula would add to the excitement of the game in the age of Twenty20. It would also negate the luck factor of the toss and provide a level-playing field.
"Today, we can tell the result of close to 75% of matches after the toss. We know how conditions will affect the two teams. But it (splitting the game into two innings) is not too dependent on the toss because, (if) it's a day-night match, then both the teams will have to bat under lights. And if it rains, you can plan for that too," Tendulkar had opined. The administrators Down Under seem to have taken note of Sachin's observation.

Washington August 14:
Health officials approved a new, longer-lasting "morning-after" pill to prevent pregnancy after unprotected sex.
The prescription drug, called ella, is made by French company HRA Pharma and will be sold in the United States by Watson Pharmaceuticals. It is the first emergency contraceptive approved since a five-year battle under the Bush administration ended with limited over-the-counter sales and age checks by pharmacists for a rival pill.
Ella has been shown to prevent pregnancy for up to five days after unprotected sex. The Food and Drug Administration said it cleared ella based on two clinical trials that showed the drug was safe and effective. The drug "is not intended for routine use as a contraceptive," the FDA said in a statement. Watson said it planned to launch ella in the fourth quarter of 2010. The company has not announced a price.
The drug will compete with Teva Pharmaceutical Industries Ltd's Plan B, which works for up to three days after intercourse. Plan B is available without a prescription for those aged 17 and older, but ella will require a prescription for all ages. Plan B, first cleared as a prescription drug in 1999, saw dozens of medical and other groups push for over-the-counter use starting in 2001. The Bush administration approved limited "behind-the-counter" sales in 2006.
Watson sells a generic version of Plan B called Next Choice. While morning-after pills have not been huge money-makers, they have generated controversy, especially in the United States. Sex, birth control and abortion are perennial political hotbeds even though emergency birth control drugs had been available for decades. Conservatives, Republicans and other critics have said making another morning-after pill available -- one that works even longer after sex -- will further promote promiscuity.
They also question ella's safety and say the drug is more akin to an abortion pill than birth control. "The FDA opted against including the critical fact that ella can cause an abortion on a baby already implanted in its mother's womb in the drug labeling information," Jeanne Monahan, director of the Center for Human Dignity at the Family Research Council, said in a statement. Women's groups, Democrats and other advocates say the pills offer women much-needed options to plan their families and provide a safety net when other birth control methods fail or women are raped.
"Every woman deserves every option available to prevent an unplanned pregnancy, and there are many reasons why a woman may face the risk of unintended pregnancy -- from failure or improper use of birth control, to sexual assault," Cecile Richards, president of Planned Parenthood Federation of America, said in a statement. Ella is a type of selective progesterone receptor modulator, making it part of a class of drugs that interfere with the hormone progesterone that is crucial for pregnancy.
The class also includes the abortion pill known as RU-486, or mifepristone, and sold as Danco Laboratories' Mifeprex. Watson said the overall pregnancy rate for women who took ella within three days of sex was 1.9 percent, lower than the anticipated rate of 5.6 percent. For women who took the drug two days to five days after sex, the pregnancy rate was 2.2 percent, lower than an expected rate of 5.5 percent.
Company officials and the FDA have said ella appears to work primarily by preventing the release of a woman's egg for up to five days after unprotected sex, although the lining of the uterus is also affected. Common side effects with ella include nausea, headache and abdominal pain, according to the company's clinical data. Women with known or suspected pregnancy and women who are breast-feeding should not use ella, the FDA said.
Known chemically as ulipristal, the drug already is sold in several European countries under the name ellaOne. HRA Pharma has said it has also begun seeking approval in other countries.